Fulcrum Asset Management’s Amphastar Pharmaceuticals AMPH Stock Holding History

Fulcrum Asset Management’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$36.2K	Buy	+1,750	New	+$35.3K	﹤0.01%	582

Other funds holding AMPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fulcrum Asset Management's AMPH Position: Q2 2026 in Review

Fulcrum Asset Management opened a new position in Amphastar Pharmaceuticals (AMPH) in Q2 2026: 1,750 shares worth $36.2K. The stake represents ﹤0.01% of the portfolio and ranks #582 among its holdings.

210 funds tracked by Wall St. Rank hold AMPH as of Q2 2026.

Fulcrum Asset Management held 1,750 shares of Amphastar Pharmaceuticals worth $36.2K as of Q2 2026.
Amphastar Pharmaceuticals was a new Fulcrum Asset Management position in Q2 2026.
Amphastar Pharmaceuticals made up ﹤0.01% of Fulcrum Asset Management's portfolio in Q2 2026, its #582 holding.
210 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2026.

Based on Fulcrum Asset Management's 13F filing for Q2 2026, filed 18 Aug 2026.